Compare Eli Lilly And Co (LLY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs BIO-TECHNE Corp — how do they compare? Eli Lilly And Co trades at $1,220.8 (market cap $1.08T), while BIO-TECHNE Corp trades at $72.23 (market cap $11.24B). The key difference: Eli Lilly And Co is far larger — about 96.1× BIO-TECHNE Corp's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | TECH | |
|---|---|---|
Market Cap | $1.08T | $11.24B |
Sector | Health | Health |
52-Week High | $1.24K | $72.29 |
52-Week Low | $639.43 | $43.31 |
Enterprise Value | $1.13T | $11.32B |
Dividend Yield | 0.57% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Bio-Techne (TECH) trades at $72.11, down 0.01% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q2 2026. The company reported Q4 2026 revenue of $321.2 million, with organic growth of 3%, and declared a $0.08 dividend. However, net income margin has declined from 25.09% in 2023 to 6.01% in 2025, and valuation ratios like P/E of 103.09 remain elevated.
The outlook is mixed: strong cash flow and institutional interest support upside, but high valuation and margin compression pose risks. Analysts are evenly split between Buy and Hold, with a consensus price target of $71.67, slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
